Refractory to Standard Therapies

Pipeline Programs↗

Active Trials↗

Companies Involved↗

Refractory to Standard Therapies is an early-stage landscape with 0 programs across 2 companies. The most active players are Klus Pharma Inc., Taiga Biotechnologies, Inc..

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Klus Pharma Inc.

0 programs

Preclinical T

Taiga Biotechnologies, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

clinical trials

Recruiting1 · 33%

Active, not recruiting1 · 33%

Unknown status1 · 33%

Clinical Trials

Trial Activity

Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies

Recruiting·—·Phase 2·NCT07309770·90 enrolled

Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)

Active, not recruiting·KKlus Pharma Inc.·Phase 1/2·NCT04152499·1,410 enrolled

Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies

Unknown status·TTaiga Biotechnologies, Inc.·Phase 1/2·NCT04640246·60 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)